Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Woodline Partners LP

Woodline Partners LP boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 15.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,852,187 shares of the company's stock after purchasing an additional 251,924 shares during the quarter. Janux Therapeutics comprises approximately 0.7% of Woodline Partners LP's investment portfolio, making the stock its 15th largest position. Woodline Partners LP owned about 3.53% of Janux Therapeutics worth $99,166,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in JANX. Russell Investments Group Ltd. increased its stake in shares of Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after acquiring an additional 442 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after acquiring an additional 599 shares during the last quarter. Kennedy Capital Management LLC increased its stake in shares of Janux Therapeutics by 7.9% in the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock worth $681,000 after acquiring an additional 928 shares during the last quarter. MetLife Investment Management LLC increased its stake in shares of Janux Therapeutics by 5.8% in the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock worth $926,000 after acquiring an additional 949 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after acquiring an additional 1,095 shares during the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Janux Therapeutics

In other news, Director Ra Capital Management, L.P. bought 110,206 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was bought at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the acquisition, the director now directly owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. The trade was a 1.10% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $30.00, for a total value of $100,020.00. Following the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $2,464,170. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,001 shares of company stock worth $313,964 in the last three months. 29.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on JANX shares. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Scotiabank cut their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Finally, Wedbush reissued an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $95.25.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX traded up $0.01 during midday trading on Friday, reaching $25.22. 1,181,341 shares of the company's stock were exchanged, compared to its average volume of 874,124. The firm's 50 day simple moving average is $28.03 and its two-hundred day simple moving average is $39.59. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -21.56 and a beta of 3.24. Janux Therapeutics, Inc. has a fifty-two week low of $22.48 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.